An immuno-oncology triplet from Roche shows promise in mouse models of several tumors
from Fierce Biotech
CD40, a receptor on the surface of immune cells, has long been of interest in oncology research because activating it stimulates cancer-killing T cells. Several companies have developed antibody drugs targeting CD40, including Roche, but they’ve proven disappointing on their own in clinical trials. Scientists at the University of Basel say they may have found a way to improve responses to CD40 antibodies.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063